Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BCAL DiagnosticsASX:BDX EV-to-OCF is -3.48 as of Aug. 16, 2026. The stock has 3 warning signs investors should review. Among 212 Medical Diagnostics & Research companies, BCAL Diagnostics ranks better than 66.51% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, BCAL Diagnostics's Enterprise Value is A$20.76 Mil.
BCAL Diagnostics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was A$-5.96 Mil. Therefore, BCAL Diagnostics's EV-to-OCF for today is -3.48.
The historical rank and industry rank for BCAL Diagnostics's EV-to-OCF or its related term are showing as below:
ASX:BDX'
s EV-to-OCF Range Over the Past 10 Years
Min: -3.48 Med: 0 Max: -3.48
Current: -3.48
During the past 4 years, the highest EV-to-OCF of BCAL Diagnostics was -3.48. The lowest was -3.48. And the median was .
ASX:BDX's EV-to-OCF is ranked better than 66.51% of 212
companies
in the Medical Diagnostics & Research industry
Industry Median: 6.235
vs ASX:BDX: -3.48
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
BCAL Diagnostics's PE Ratio (TTM) for today is calculated as:
BCAL Diagnostics's share price for today is A$0.056.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. BCAL Diagnostics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.020.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
BCAL Diagnostics EV-to-OCF Related Terms
BCAL Diagnostics EV-to-OCF Historical Data
* Premium members only.
The historical data trend for BCAL Diagnostics's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, BCAL Diagnostics's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BCAL Diagnostics EV-to-OCF vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, BCAL Diagnostics's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where BCAL Diagnostics's EV-to-OCF falls into.
BCAL Diagnostics's current Enterprise Value is A$20.76 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. BCAL Diagnostics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was A$-5.96 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BCAL Diagnostics (ASX:BDX) has a EV-to-OCF of -3.48 as of Aug. 16, 2026. According to the industry distribution chart, BCAL Diagnostics ranks #71 out of 212 companies in the Medical Diagnostics & Research industry, placing it in the top 33.5%.
Is BCAL Diagnostics' EV-to-OCF too high?
BCAL Diagnostics' current EV-to-OCF is -3.48. Based on the distribution chart, BCAL Diagnostics ranks #71 out of 212 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint.
How does BCAL Diagnostics' EV-to-OCF compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, BCAL Diagnostics ranks #71 out of 212 companies for EV-to-OCF. This puts BCAL Diagnostics in the upper half of its industry. The industry median EV-to-OCF is 6.24. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Diagnostics & Research company?
The median EV-to-OCF among Medical Diagnostics & Research companies is 6.24, based on 212 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Diagnostics & Research industry, the median EV-to-OCF is 6.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BCAL Diagnostics's current EV-to-OCF is -3.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BCAL Diagnostics stock overvalued right now?
BCAL Diagnostics (ASX:BDX) has a current EV-to-OCF of -3.48. The current EV-to-OCF is -3.48. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For BCAL Diagnostics (ASX:BDX), the current EV-to-OCF is -3.48 as of Aug. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BCAL Diagnostics Ltd is a biotechnology company developing a novel blood screening test to improve the early diagnosis and monitoring of breast cancer that is safe, cost-effective, accurate, and available to all women regardless of age, race, and geographic location.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:BDX has been successfully added to your 
